The Hong Kong insurer’s steady expansion across key non-life segments and capital support from its parent underpin improved performance and balance sheet strength.
The insurer recorded a 9% return on equity in the first half of 2025, supported by fair-value gains that helped offset weaker recurring investment income.
The Indian reinsurer’s return on equity rose to 9.2% in FY 2025 on stronger investment income, but elevated COR kept underwriting performance in the red.
